How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | TMOTHERMO FISHER SCIENTIFIC INC. | DHRDANAHER CORP /DE/ | AAGILENT TECHNOLOGIES, INC. | IQVIQVIA HOLDINGS INC. | Median of the restexcluding TMO |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $676.54▼ 17.48 (2.52%) | $229.75▼ 4.11 (1.76%) | $177.75▲ 4.74 (2.74%) | $276.63▲ 8.78 (3.28%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 7.3/10 | 9.0/10 | 9.0/10 | 6.0/10 | 9.0/10 |
| Market value | $255.23B | $162.41B | $50.31B | $46.92B | |
| Revenue | $44.56B | $24.57B | $6.95B | $16.31B | |
| Profit | $6.70B | $3.61B | $1.30B | $1.36B | |
| Revenue growthChange in sales versus the prior year. | 3.9% | 2.9% | 6.7% | 5.9% | 5.9% |
| Gross marginShare of sales left after the direct cost of producing them. | — | 59.1% | 52.4% | 33.3% | 52.4% |
| Operating marginShare of sales left after running the business, before interest and tax. | 17.4% | 19.1% | 21.3% | 13.4% | 19.1% |
| Profit marginProfit kept from each dollar of sales. | 15.0% | 14.7% | 18.8% | 8.3% | 14.7% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 14.1% | 21.4% | 16.6% | 12.6% | 16.6% |
| Return on equityProfit against the owners' stake in the company. | 12.6% | 6.9% | 19.3% | 20.9% | 19.3% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 8.2% | 6.0% | 16.2% | 9.2% | 9.2% |
| P/E ratioPrice paid per dollar of annual profit. | 38.07x | 44.94x | 38.61x | 34.50x | 38.61x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | 32.75x | 32.39x | 29.36x | 18.24x | 29.36x |
| Price to book | 4.78x | 3.09x | 7.46x | 7.21x | 7.21x |
| Debt to equityTotal liabilities compared with owners' stake. | 1.07x | 0.59x | 0.89x | 3.59x | 0.89x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 6/8 | 5/9 | 6/9 | 5/9 | 5.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | safe | safe | grey |
How TMO compares with the others
- TMO's operating margin of 17.4% is lower than the median of the other companies selected (19.1%).
- Its revenue growth of 3.9% is in line with the median of the other companies selected (5.9%).
- It trades at a P/E in line with the median of the other companies selected (38.1x against 38.6x).
- Its liabilities are higher relative to equity than the median of the other companies selected: 1.1x against 0.9x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.